Data Manager

Associate Director, Statistical Programing

Director, Biostatistician

Senior Manager, Medical Review – Medical Affairs

Associate Director, Medical Affairs Content Development 

Medical Science Liaison (MSL) Rheumatology – West

Medical Science Liaison (MSL) Rheumatology – East

Medical Science Liaison (MSL) Neurology – Mountain

Medical Science Liaison (MSL) Neurology - Southeast

Medical Science Liaison (MSL) Neurology – South Central

Medical Science Liaison (MSL) Neurology – Northeast

Medical Science Liaison (MSL) Neurology – Midwest

Medical Science Liaison (MSL) Neurology – West Coast 

Senior Clinical Business Operations Manager 

eTMF Specialist, Clinical Operations 

Senior/Clinical Trial Manager (CTM)

Senior Director, Field Medical Lead-West

Senior Director, Field Medical Lead-East 

Principal Medical Writer

VP, Supply Chain and Manufacturing

Associate/Director, Regulatory Submissions

Director, GLP/GCP/GVP Quality 

Director, Safety Physician 

Senior/Medical Director 

Associate Director/Director, Global Clinical Operations

Vice President, Clinical Operations

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

76Bio

A-Alpha Bio

A2 Biotherapeutics

AAVogen

ACELYRIN

ADAXION Therapeutics

AI Proteins

AIRNA Bio

ALX Oncology

AN2 Therapeutics

AOA Dx

ARTBIO

AS2 Bio Inc

AUM BioTech

AVROBIO

Ab Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

Acepodia

Achieve Life Sciences

Acomhal Research

Acrivon Therapeutics

Actym Therapeutics, Inc.

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Adiso Therapeutics

Aditum Bio

Admera Health

Adverum Biotechnologies

Aeglea BioTherapeutics

Aera Therapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

AgBiome

Agastiya Biotech

Agena Bioscience

AiViva Biopharma

Ainnocence

AivoCode

Aixa Bio

Akero Therapeutics

Akita Biosciences

Akouos

Akttyva Therapeutics

Alamar Biosciences

Aldebaran Therapeutics

Alector

Alida Biosciences

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

Alltrna

AlpaLifeBio

Alpha-9 Oncology

Alphabioregen

AltPep

Alterome Therapeutics

Altis Biosystems

Alto Neuroscience

Alumis

Alveo Technologies

Alveolus Bio

Alzheon

AmbAgon Therapeutics

Amberstone Biosciences

Amolyt Pharma

Amylyx Pharmaceuticals

AnHeart Therapeutics

Anagram Therapeutics

Ancora Biotech LLC

Andes

Andson Biotech

Anebulo Pharmaceuticals

Angiex

Angiocrine Bioscience

Anima Biotech

Ankyra

Annexon Biosciences

Anodyne Nanotech

Anokion

Ansa Biotechnologies

Vor Biopharma is engineering hematopoietic stem cells (HSCs) to improve the efficacy of treating blood cancers. Current therapeutic strategies for blood cancers involve identifying unique targets on cancer cells. Vor is changing this paradigm by instead engineering healthy cells and making them invisible to targeted therapies. Vor’s approach reduces on-target toxicity of healthy cells by genetically modifying HSCs to remove surface targets expressed by cancer cells. Engineered HSCs are then transplanted back to patients and are then treatment resistant. Vor’s lead product, VOR33, showed promising preclinical data and is now entering clinical trials. The company is also conducting ongoing discovery efforts using their proprietary platform to identify additional surface targets. 

<p>Vor Biopharma is engineering hematopoietic stem cells (HSCs) to improve the efficacy of treating blood cancers. Current therapeutic strategies for blood cancers involve identifying unique targets on cancer cells. Vor is changing this paradigm by instead engineering healthy cells and making them invisible to targeted therapies. Vor’s approach reduces on-target toxicity of healthy cells by genetically modifying HSCs to remove surface targets expressed by cancer cells. Engineered HSCs are then transplanted back to patients and are then treatment resistant. Vor’s lead product, VOR33, showed promising preclinical data and is now entering clinical trials. The company is also conducting ongoing discovery efforts using their proprietary platform to identify additional surface targets. </p>


Find a biotech startup job.